Preparing for Pandemics using Canary Health Technologies Cloud Based Rapid Breath Analysis Platform
Rapid breath analysis platform for COVID19 by Canary Health Technologies can help prepare for pandemics and mitigate their terrible effects
Pandemics such as COVID19 caused by novel emerging or re-emerging infectious diseases lead to high mortality and morbidity world-wide when left uncontrolled. We are evaluating the integration of Canary’s Airostotle breath data in order to provide timely support for this pandemic. This type of approach requires two major innovations.
-
First, data that is obtained should be shared with the global community instantly through Canary’s sentinel cloud platform. The rapid integration of complex breath data will optimize the deployment of key personnel and resources.
-
Second, Airostotle breath technology is fast and has high throughput. The exhaled breath analysis by Canary’s Airostotle platform is a simple, rapid and non-invasive methodology. Breath contains hundreds of volatile organic compounds that are altered by infection and inflammation. The molecular signature of breath (breath pattern) can be obtained using Canary’s rapid breath analysis platform, Airostotle.
Canary’s Airostotle Real-Time Differential Sensor Technology
The exhaled breath is sampled directly utilizing Airostotle’s breath sensor system and a response is given in under 5 minutes. Airostotle has an array of differentially selective sensors that show interactions with Volatile Organic Compounds (VOCs) in the exhaled breath of users. This sensor data creates a breath signature, a digital pattern of sensor response changes for the individual sensors that reflects the unique profile of the breath VOC mixture, that can be furthered classified using Artificial Intelligence. These breath patterns can be stored in an online database (a “breath-cloud”) and coupled to clinical data. Comparison of the digitized breath patterns of a suspected subject to the breath-cloud allows for a rapid decision on the presence or absence of a pathogen. Unlike other diagnostics, embedded machine learning drives Airostotle continuous detection real-time sensitivity improvements.
Canary’s Airostotle Real-Time Breath Analysis Technology is targeting COVID-19 detection:
-
It can be deployed at the point of care and for home use rapidly. Results to the operator in under 5 minutes.
-
It is simple to use by untrained operators or at home.
-
There is a simple supply chain without the need for reagents or swabs. The main analyte is exhaled breath meaning supply is reliable.
-
It is designed to detect in the very early asymptomatic window (0 to 5 days post exposure) as well as in the post infectious window more than 14 days after infection and up to 25 days post-infection.
-
Asymptomatic detection of COVID-19 disease means early identification of contagious carriers which can help reduce the spread of the disease.
-
Clinical trials are currently planned with leading researchers worldwide.
-
The cloud-based platform can be rapidly to scaled and provide surveillance data instantly.
Since infectious disease outbreaks typically emerge unexpectedly and can advance swiftly, rapid detection of (re)-emerging pathogens is of utmost importance. Rapid detection allows for optimal preparation on the level of individuals (e.g., early recognition, quarantine and swift start of adequate treatment of individual patients), on the level of populations (e.g., fast vaccination and other preventive measures), and on the level of organizations (e.g., timely preparation and education of hospital personnel, adequate distribution of therapeutics and medical equipment, and preparation of research infrastructures), thereby hopefully limiting burden caused by each novel rapidly spreading disease.
